Clinical trial
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell…
NCT00118235 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00118235 |
|---|---|
| Title | Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer |
| Official title | Cisplatin, Irinotecan and Bevacizumab (NSC# 704865) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extensive Stage Small Cell Lung Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | cisplatin, irinotecan hydrochloride, bevacizumab, laboratory biomarker analysis |
| Enrollment | 72 |
| Start date | Dec 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Jul 1, 2011 |
| First posted | Jul 11, 2005 |
| Last update posted | Jun 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: